Celecoxib Alleviates Pathological Cardiac Hypertrophy and Fibrosis Via M1-like Macrophage Infiltration in Neonatal Mice

Overview

Journal iScience

Publisher Cell Press

Date 2021 Mar 22

PMID 33748715

Citations 7

Authors

Yanli Zhao

Qi Zheng

Hanchao Gao

Mengtao Cao

Huiyun Wang

Rong Chang

Changchun Zeng

Affiliations

Soon will be listed here.

Abstract

Cardiac hypertrophy is an adaptive response to all forms of heart disease, including hypertension, myocardial infarction, and cardiomyopathy. Cyclooxygenase-2 (COX-2) overexpression results in inflammatory response, cardiac cell apoptosis, and hypertrophy in adult heart after injury. However, immune response-mediated cardiac hypertrophy and fibrosis have not been well documented in injured neonatal heart. This study showed that cardiac hypertrophy and fibrosis are significantly attenuated in celecoxib (a selective COX-2 inhibitor)-treated P8 ICR mice after cryoinjury. Molecular and cellular profiling of immune response shows that celecoxib inhibits the production of cytokines and the expression of adhesion molecular genes, increases the recruitment of M1-like macrophage at wound site, and alleviates cardiac hypertrophy and fibrosis. Furthermore, celecoxib administration improves cardiac function at 4 weeks after injury. These results demonstrate that COX-2 inhibition promotes the recruitment of M1-like macrophages during early wound healing, which may contribute to the suppression of cardiac hypertrophy and fibrosis after injury.

Citing Articles

Crosstalk between macrophages and immunometabolism and their potential roles in tissue repair and regeneration.

Ma H, Gao L, Chang R, Zhai L, Zhao Y Heliyon. 2024; 10(18):e38018.

PMID: 39381218 PMC: 11458987. DOI: 10.1016/j.heliyon.2024.e38018.

Virtual drug screen reveals context-dependent inhibition of cardiomyocyte hypertrophy.

Eggertsen T, Saucerman J Br J Pharmacol. 2023; 180(21):2721-2735.

PMID: 37302817 PMC: 10592153. DOI: 10.1111/bph.16163.

Targeting neuro-immune systems to achieve cardiac tissue repair following myocardial infarction: A review of therapeutic approaches from in-vivo preclinical to clinical studies.

Smith S, Ascione R Pharmacol Ther. 2023; 245:108397.

PMID: 36996910 PMC: 7616359. DOI: 10.1016/j.pharmthera.2023.108397.

The link between immunity and hypertension in the kidney and heart.

Benson L, Guo Y, Deck K, Mora C, Liu Y, Mu S Front Cardiovasc Med. 2023; 10:1129384.

PMID: 36970367 PMC: 10034415. DOI: 10.3389/fcvm.2023.1129384.

Treatment of myocardial interstitial fibrosis in pathological myocardial hypertrophy.

Zhu F, Li P, Sheng Y Front Pharmacol. 2022; 13:1004181.

PMID: 36249793 PMC: 9561344. DOI: 10.3389/fphar.2022.1004181.

References

Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M . Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003; 107(3):405-9. DOI: 10.1161/01.cir.0000051361.69808.3a. View

Rumzhum N, Ammit A . Cyclooxygenase 2: its regulation, role and impact in airway inflammation. Clin Exp Allergy. 2015; 46(3):397-410. DOI: 10.1111/cea.12697. View

Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M . The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25(12):677-86. DOI: 10.1016/j.it.2004.09.015. View

Lavine K, Epelman S, Uchida K, Weber K, Nichols C, Schilling J . Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. Proc Natl Acad Sci U S A. 2014; 111(45):16029-34. PMC: 4234568. DOI: 10.1073/pnas.1406508111. View

Wang Y, Dembowsky K, Chevalier E, Stuve P, Korf-Klingebiel M, Lochner M . C-X-C Motif Chemokine Receptor 4 Blockade Promotes Tissue Repair After Myocardial Infarction by Enhancing Regulatory T Cell Mobilization and Immune-Regulatory Function. Circulation. 2019; 139(15):1798-1812. PMC: 6467561. DOI: 10.1161/CIRCULATIONAHA.118.036053. View

Wu R, Laplante M, de Champlain J . Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats. Hypertension. 2005; 45(6):1139-44. DOI: 10.1161/01.HYP.0000164572.92049.29. View

Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U . Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol. 2002; 283(3):H1253-62. DOI: 10.1152/ajpheart.00578.2001. View

Wang B, Bertucci M, Ma J, Adrahtas A, Cheung R, Krum H . Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone. Clin Exp Pharmacol Physiol. 2010; 37(9):912-8. DOI: 10.1111/j.1440-1681.2010.05405.x. View

Ding J, Lei L, Liu S, Zhang Y, Yu Z, Su Y . Macrophages are necessary for skin regeneration during tissue expansion. J Transl Med. 2019; 17(1):36. PMC: 6341552. DOI: 10.1186/s12967-019-1780-z. View

10.

Wynn T, Vannella K . Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity. 2016; 44(3):450-462. PMC: 4794754. DOI: 10.1016/j.immuni.2016.02.015. View

11.

Robertson R . The COX-2/PGE/EP3/G/cAMP/GSIS Pathway in the Islet: The Beat Goes On. Diabetes. 2017; 66(6):1464-1466. PMC: 5440014. DOI: 10.2337/dbi17-0017. View

12.

Bea F, Blessing E, Bennett B, Kuo C, Campbell L, Kreuzer J . Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc Res. 2003; 60(1):198-204. DOI: 10.1016/s0008-6363(03)00464-4. View

13.

Lai S, Marin-Juez R, Stainier D . Immune responses in cardiac repair and regeneration: a comparative point of view. Cell Mol Life Sci. 2018; 76(7):1365-1380. PMC: 6420886. DOI: 10.1007/s00018-018-2995-5. View

14.

Jurgensen H, Silva L, Krigslund O, van Putten S, Madsen D, Behrendt N . CCL2/MCP-1 signaling drives extracellular matrix turnover by diverse macrophage subsets. Matrix Biol Plus. 2021; 1:100003. PMC: 7852312. DOI: 10.1016/j.mbplus.2019.03.002. View

15.

Homma T, Kinugawa S, Takahashi M, Sobirin M, Saito A, Fukushima A . Activation of invariant natural killer T cells by α-galactosylceramide ameliorates myocardial ischemia/reperfusion injury in mice. J Mol Cell Cardiol. 2013; 62:179-88. DOI: 10.1016/j.yjmcc.2013.06.004. View

16.

Camitta M, Gabel S, Chulada P, Bradbury J, Langenbach R, Zeldin D . Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. Circulation. 2001; 104(20):2453-8. DOI: 10.1161/hc4401.098429. View

17.

De Stefano G, Zanati-Basan S, De Stefano L, Oliveira E Silva V, Xavier P, Barretti P . Aldosterone is associated with left ventricular hypertrophy in hemodialysis patients. Ther Adv Cardiovasc Dis. 2016; 10(5):304-13. PMC: 5933569. DOI: 10.1177/1753944716644583. View

18.

Guo Y, Bao W, Wu W, Shinmura K, Tang X, Bolli R . Evidence for an essential role of cyclooxygenase-2 as a mediator of the late phase of ischemic preconditioning in mice. Basic Res Cardiol. 2001; 95(6):479-84. PMC: 3691687. DOI: 10.1007/s003950070024. View

19.

Wang Z, Cui M, Shah A, Tan W, Liu N, Bassel-Duby R . Cell-Type-Specific Gene Regulatory Networks Underlying Murine Neonatal Heart Regeneration at Single-Cell Resolution. Cell Rep. 2020; 33(10):108472. PMC: 7774872. DOI: 10.1016/j.celrep.2020.108472. View

20.

Manabe I, Shindo T, Nagai R . Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res. 2002; 91(12):1103-13. DOI: 10.1161/01.res.0000046452.67724.b8. View